October 14, 2019 Bio/Pharma/CRO PR/Corporate

Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

Basel, 14 October 2019 Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate mofetil Study... Read more

October 10, 2019 Clinical Research/Diagn. Microscopy PR/Corporate

GE Healthcare Selected as Vendor of Choice for NYC Health + Hospitals $224 Million Investment to Upgrade Medical Imaging Technology System-Wide

230 medical imaging units will be replaced and updated within first four years Equipment will support the public health system’s goal of standardizing care and providing patients modernized, state-of-the-art imaging technology New York, NY – October 10, 2019 –NYC Health + Hospitals today announced that it is investing $224 million over ten-years to upgrade medical imaging technology... Read more

October 10, 2019 Life Science Tools PR/Corporate Product Launch

Highly Accurate SMRT Sequencing for Human Genetics to Be Showcased at ASHG 2019 Annual Meeting

MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that more than 50 presentations will include data from the company’s Single Molecule, Real-Time (SMRT®) sequencing platforms at next week’s American Society for Human Genetics (ASHG) 2019... Read more

October 9, 2019 Environ, Ag./Food & Bev Lab Top-10 Life Science Tools PR/Corporate

Danaher Schedules Third Quarter 2019 Earnings Conference Call

WASHINGTON, Oct. 9, 2019 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that it will webcast its quarterly earnings conference call for the third quarter 2019 on Thursday, October 24, 2019 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s... Read more

October 7, 2019 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

vertX Bioprocess Conference Convenes Biotech and Biopharma Leaders to Accelerate Industry Collaboration

vertX Bioprocess Conference Convenes Biotech and Biopharma Leaders to Accelerate Industry Collaboration Thermo Fisher Scientific’s forum focuses on strategies to expedite biotherapeutic development and commercialization LOGAN, Utah, Oct. 7, 2019 /PRNewswire/ — To discuss the future strategies of biologics development and commercialization, Thermo Fisher Scientific hosted the inaugural vertX Bioprocess Conference on Thursday, September 26... Read more

October 6, 2019 Microscopy Molecular Spectroscopy PR/Corporate

Conference Review: 16th Confocal Raman Imaging Symposium

The international chemical imaging community gathered once again in Ulm, Germany to share and discuss results, methods and technologies related to Raman microscopy. Almost one hundred attendees heard presentations arranged into distinct sessions under the headings: Nanotechnology and Low-dimensional Materials, Geosciences, Life Sciences, Applied Chemical Analysis, and Contributed Talks. Poster sessions provided a relaxed forum... Read more

October 2, 2019 Chromatography Clinical Research/Diagn. Lab Top-10 PR/Corporate

Agilent Receives Approval for First PD-L1 Companion Diagnostic in China

Agilent Receives Approval for First PD-L1 Companion Diagnostic in China SANTA CLARA, Calif., October 2, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the National Medical Products Administration (NMPA, formerly the China Food and Drug Administration) has approved its PD-L1 IHC 22C3 pharmDx assay for use in China. The assay is now approved as... Read more

October 1, 2019 Acad, Gov/Utilities PR/Corporate

Luminex Receives FDA 510(k) Clearance for the ARIES® MRSA Assay

  AUSTIN, Texas, Oct. 1, 2019 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced that the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES® MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA)... Read more

September 30, 2019 Bio/Pharma/CRO PR/Corporate

Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

Basel, 30 September 2019 Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening... Read more